| Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents (NCT02936752) | National Cancer Institute (NCI) | 2017-06-23 |
| Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis (NCT02968810) | National Cancer Institute (NCI) | 2017-06-21 |
| Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery (NCT03148275) | National Cancer Institute (NCI) | 2017-06-20 |
| Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer (NCT03072160) | National Cancer Institute (NCI) | 2017-06-16 |
| Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC) (NCT03111732) | National Cancer Institute (NCI) | 2017-06-14 |
| Breadth of Donor Options for People With Inherited Diseases Requiring Allogeneic Hematopoietic Stem Cell Transplant in the Era of Alternative Donor Transplants Using Post-Transplantation Cyclophosphamide (NCT03188419) | National Cancer Institute (NCI) | 2017-06-14 |
| 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer (NCT03173924) | National Cancer Institute (NCI) | 2017-06-06 |
| Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology (NCT03092518) | National Cancer Institute (NCI) | 2017-06-05 |
| Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors (NCT02631733) | National Cancer Institute (NCI) | 2017-05-31 |
| Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia (NCT02791919) | National Cancer Institute (NCI) | 2017-05-25 |
| Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer (NCT02862275) | National Cancer Institute (NCI) | 2017-05-24 |
| Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors (NCT02589522) | National Cancer Institute (NCI) | 2017-05-22 |
| Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors (NCT03189108) | National Cancer Institute (NCI) | 2017-05-22 |
| Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer (NCT02898207) | National Cancer Institute (NCI) | 2017-05-19 |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors (NCT02867592) | National Cancer Institute (NCI) | 2017-05-18 |
| Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT02627443) | National Cancer Institute (NCI) | 2017-05-16 |
| Cervix Image Sharing Protocol (CISP) (NCT03179306) | National Cancer Institute (NCI) | 2017-05-15 |
| Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases (NCT02993146) | National Cancer Institute (NCI) | 2017-05-08 |
| Gastric Cancer Precursor Lesions (GCPL) Study (NCT03188406) | National Cancer Institute (NCI) | 2017-05-02 |
| Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy (NCT03055013) | National Cancer Institute (NCI) | 2017-04-28 |
| Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery (NCT02893930) | National Cancer Institute (NCI) | 2017-04-28 |
| Long-Term Follow up of Patients Undergoing Hematopoietic Stem Cell Transplantation, Cellular Therapy, or Gene Therapy (NCT03000244) | National Cancer Institute (NCI) | 2017-04-26 |
| Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma (NCT03141684) | National Cancer Institute (NCI) | 2017-04-25 |
| A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy (NCT03076554) | National Cancer Institute (NCI) | 2017-04-19 |
| PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer (NCT02933255) | National Cancer Institute (NCI) | 2017-04-18 |
| Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer (NCT02567422) | National Cancer Institute (NCI) | 2017-04-17 |
| Retrospective Study of Viral Reactivation Across All Bone Marrow Transplant Protocols Since 2010 (NCT03111745) | National Cancer Institute (NCI) | 2017-04-13 |
| Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST) (NCT03109301) | National Cancer Institute (NCI) | 2017-04-07 |
| Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers (NCT02830724) | National Cancer Institute (NCI) | 2017-04-06 |
| Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (NCT02484430) | National Cancer Institute (NCI) | 2017-04-06 |
| Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004 (NCT03050814) | National Cancer Institute (NCI) | 2017-04-05 |
| Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia (NCT02782949) | National Cancer Institute (NCI) | 2017-04-04 |
| Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement (NCT02828358) | National Cancer Institute (NCI) | 2017-04-01 |
| Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer (NCT02849496) | National Cancer Institute (NCI) | 2017-03-30 |
| Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (NCT02788201) | National Cancer Institute (NCI) | 2017-03-27 |
| Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I) (NCT04439227) | National Cancer Institute (NCI) | 2017-03-24 |
| Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J) (NCT06136897) | National Cancer Institute (NCI) | 2017-03-23 |
| Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer (NCT02503722) | National Cancer Institute (NCI) | 2017-03-23 |
| Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C) (NCT06390839) | National Cancer Institute (NCI) | 2017-03-22 |
| T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas (NCT03049449) | National Cancer Institute (NCI) | 2017-03-17 |
| Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer (NCT02844816) | National Cancer Institute (NCI) | 2017-03-13 |
| Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M) (NCT06390865) | National Cancer Institute (NCI) | 2017-03-12 |
| Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L) (NCT06385496) | National Cancer Institute (NCI) | 2017-03-12 |
| Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer (NCT02921269) | National Cancer Institute (NCI) | 2017-03-10 |
| Discovery and Validation of Plasma DNA Methylation Biomarker for Detection of Stomach Cancer (NCT03076567) | National Cancer Institute (NCI) | 2017-03-09 |
| Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas (NCT03030417) | National Cancer Institute (NCI) | 2017-02-27 |
| Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma (NCT02631746) | National Cancer Institute (NCI) | 2017-02-23 |
| Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer (NCT02948426) | National Cancer Institute (NCI) | 2017-02-08 |
| Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery (NCT04955808) | National Cancer Institute (NCI) | 2017-02-07 |
| Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery (NCT02775851) | National Cancer Institute (NCI) | 2017-02-06 |
| Prospective Evaluation and Molecular Profiling in People With Gastric Tumors (NCT03027427) | National Cancer Institute (NCI) | 2017-02-01 |
| Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer (NCT02567409) | National Cancer Institute (NCI) | 2017-01-31 |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (NCT02834013) | National Cancer Institute (NCI) | 2017-01-30 |
| E7 TCR T Cells for Human Papillomavirus-Associated Cancers (NCT02858310) | National Cancer Institute (NCI) | 2017-01-27 |
| Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer (NCT03030404) | National Cancer Institute (NCI) | 2017-01-27 |
| Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) (NCT02689453) | National Cancer Institute (NCI) | 2017-01-19 |
| Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer (NCT02954874) | National Cancer Institute (NCI) | 2017-01-18 |
| Chile Biliary Longitudinal Study (NCT02692911) | National Cancer Institute (NCI) | 2017-01-11 |
| Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer (NCT02921256) | National Cancer Institute (NCI) | 2017-01-11 |
| Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics (NCT03027401) | National Cancer Institute (NCI) | 2017-01-10 |
| Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors (NCT02780804) | National Cancer Institute (NCI) | 2017-01-06 |
| CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer (NCT03002623) | National Cancer Institute (NCI) | 2016-12-22 |
| Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma (NCT02581930) | National Cancer Institute (NCI) | 2016-12-16 |
| Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma (NCT02942264) | National Cancer Institute (NCI) | 2016-12-14 |
| Hyperthyroid Follow-Up Study (NCT02989103) | National Cancer Institute (NCI) | 2016-12-06 |
| Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer (NCT02598557) | National Cancer Institute (NCI) | 2016-12-06 |
| Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma (NCT02775812) | National Cancer Institute (NCI) | 2016-11-28 |
| Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma (NCT02568553) | National Cancer Institute (NCI) | 2016-11-15 |
| Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma (NCT02101905) | National Cancer Institute (NCI) | 2016-11-07 |
| Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation (NCT02759731) | National Cancer Institute (NCI) | 2016-11-01 |
| Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V) (NCT06390826) | National Cancer Institute (NCI) | 2016-11-01 |
| Early Detection of Esophageal Cancer (NCT00341523) | National Cancer Institute (NCI) | 2016-11-01 |
| FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer (NCT02890355) | National Cancer Institute (NCI) | 2016-10-27 |
| Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (NCT02443077) | National Cancer Institute (NCI) | 2016-10-12 |
| Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer (NCT02417701) | National Cancer Institute (NCI) | 2016-10-06 |
| Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT02503709) | National Cancer Institute (NCI) | 2016-09-30 |
| Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists (NCT02911155) | National Cancer Institute (NCI) | 2016-09-21 |
| Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis (NCT02743364) | National Cancer Institute (NCI) | 2016-09-19 |
| Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases (NCT02595905) | National Cancer Institute (NCI) | 2016-09-15 |
| Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma (NCT02520791) | National Cancer Institute (NCI) | 2016-09-13 |
| Natural History of and Specimen Banking for People With Tumors of the Central Nervous System (NCT02851706) | National Cancer Institute (NCI) | 2016-09-01 |
| A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors (NCT02498613) | National Cancer Institute (NCI) | 2016-08-31 |
| Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer (NCT02520778) | National Cancer Institute (NCI) | 2016-08-30 |
| Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT02595892) | National Cancer Institute (NCI) | 2016-08-25 |
| Collection of Peripheral Blood Mononuclear Cells (PBMCs) From Healthy People for the Expansion of T Cells for Adoptive Cell Therapy (NCT02821806) | National Cancer Institute (NCI) | 2016-08-08 |
| Avelumab for People With Recurrent Respiratory Papillomatosis (NCT02859454) | National Cancer Institute (NCI) | 2016-08-06 |
| Linkage of Medicaid Enrollment Information to Surveillance, Epidemiology and End Results Data (NCT02875327) | National Cancer Institute (NCI) | 2016-08-05 |
| Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors (NCT02810418) | National Cancer Institute (NCI) | 2016-08-03 |
| Self-Affirmation: Construct Validity (NCT02317367) | National Cancer Institute (NCI) | 2016-07-31 |
| Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1) (NCT06357975) | National Cancer Institute (NCI) | 2016-07-29 |
| Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma (NCT02798536) | National Cancer Institute (NCI) | 2016-07-27 |
| Helicobacter Pylori Genome Project (HpGP) (NCT02788214) | National Cancer Institute (NCI) | 2016-07-27 |
| Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed (NCT02761057) | National Cancer Institute (NCI) | 2016-07-25 |
| M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT02595931) | National Cancer Institute (NCI) | 2016-07-22 |
| Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) (NCT02595944) | National Cancer Institute (NCI) | 2016-07-22 |
| Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2) (NCT06360575) | National Cancer Institute (NCI) | 2016-07-20 |
| Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma (NCT02839681) | National Cancer Institute (NCI) | 2016-07-19 |
| Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer (NCT02642042) | National Cancer Institute (NCI) | 2016-07-18 |
| Differential Influences of Integral and Incidental Emotion on Cancer-related Judgments and Decision Making (NCT02829554) | National Cancer Institute (NCI) | 2016-07-08 |
| Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy (NCT02839694) | National Cancer Institute (NCI) | 2016-07-07 |